American Heart Association

The CAVIAR trial demonstrated that alirocumab combined with rosuvastatin safely reduced LDL cholesterol levels by more than 50% in heart transplant patients within one year.

The TUXEDO-2 trial found that prasugrel-based dual antiplatelet therapy was more effective than ticagrelor in preventing heart attack, stroke, bleeding complications, and death in diabetic patients with multivessel disease after stent placement.

A large retrospective study of 346,667 patients found that GLP-1 receptor agonists do not increase pancreatitis risk in patients with elevated triglycerides, challenging longstanding clinical concerns.

The META-AF study found that 78% of overweight/obese adults with atrial fibrillation who took metformin after catheter ablation remained free from AFib episodes for one year, compared to 58% in the usual care group.

The OPTIMA-AF trial demonstrated that one month of dual clot-preventing therapy followed by single anticoagulant treatment was as effective as 12 months of dual therapy in preventing stroke, heart attack, and death in AFib patients with coronary stents.

DR10624, a novel triple-receptor agonist targeting FGF21, glucagon, and GLP-1 receptors, demonstrated significant triglyceride reductions of 66-75% across all dose levels in a 12-week Phase II trial.

The ACE-PAS study, enrolling 21,612 patients across the United States, represents the largest prospective real-world study of wearable defibrillators to date and confirms strong safety and effectiveness of Kestra's ASSURE WCD device.

Milestone Pharmaceuticals will present poster data on etripamil's efficacy, safety, and tolerability for self-administered treatment of paroxysmal supraventricular tachycardia at AHA Scientific Sessions 2025.

A Danish registry study of over 34,000 postmenopausal women found that vaginal estrogen tablets were not associated with increased risk of recurrent ischemic stroke in women with prior stroke history.

The FDA has granted Breakthrough Device Designation to Prevencio's HART CADhs test, an AI-based multi-protein blood test for detecting obstructive coronary artery disease.